Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation.
Stacy E F
SE
Melanson
Kristen
K
Stevenson
Haesook
H
Kim
Joseph H
JH
Antin
Michael H
MH
Court
Vincent T
VT
Ho
Jerome
J
Ritz
Robert J
RJ
Soiffer
Frank C
FC
Kuo
Janina A
JA
Longtine
Petr
P
Jarolim
D000483:Alleles; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D003520:Cyclophosphamide / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D065702:Cytochrome P-450 CYP2B6; D065731:Cytochrome P-450 CYP2C19; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D010089:Oxidoreductases, N-Demethylating / Q000235:genetics*; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000401:mortality
D019653:Myeloablative Agonists; D003520:Cyclophosphamide; D001189:Aryl Hydrocarbon Hydroxylases; C585599:CYP2B6 protein, human; C045793:CYP2C19 protein, human; D065702:Cytochrome P-450 CYP2B6; D065731:Cytochrome P-450 CYP2C19; D010089:Oxidoreductases, N-Demethylating